Factors influencing skeletal maturation at diagnosis of paediatric Cushing's disease

Hormone Research

Volumn 68, Issue 5, 2007, Pages 231-235

  Peters, C J ^a   Ahmed, M L ^b   Storr, H L ^a   Davies, K M ^a   Martin, L J ^a   Allgrove, J ^a   Grossman, A B ^a   Savage, M O ^a,c  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bone age; Paediatric Cushing's disease; Skeletal maturation

Indexed keywords

CORTICOTROPIN; DEXAMETHASONE; HYDROCORTISONE; PRASTERONE SULFATE;

ADOLESCENT; AGE; ANALYTIC METHOD; ARTICLE; BIOCHEMISTRY; BODY HEIGHT; BONE AGE; BONE MATURATION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CORTICOTROPIN BLOOD LEVEL; CUSHING DISEASE; DEXAMETHASONE SUPPRESSION TEST; DISEASE DURATION; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; NIGHT; PATIENT ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

ADOLESCENT; AGE DETERMINATION BY SKELETON; BODY HEIGHT; BONE DEVELOPMENT; CHILD; CHILD, PRESCHOOL; FEMALE; GROWTH DISORDERS; HUMANS; MALE; PITUITARY ACTH HYPERSECRETION; RISK FACTORS;

EID: 34948888815     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101336     Document Type: Article

References (29)

1. Magiakou MA, Mastorakos G, Oldfield EH, Gomez MT, Doppman JL, Cutler GB Jr et al: Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med 1994;331:629-636.
2. Weber A, Trainer PJ, Grossman AB, Afshar F, Medbak S, Perry LA et al: Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome. Clin Endocrinol (Oxf) 1995;43:19-28.
3. Davies JH, Storr HL, Davies K, Monson JP, Besser GM, Afshar F et al: Final adult height and body mass index after cure of paediatric Cushing's disease. Clin Endocrinol (Oxf) 2005;62:466-472.
4. Lebrethon MC, Grossman AB, Afshar F, Plowman PN, Besser GM, Savage MO: Linear growth and final height after treatment for Cushing's disease in childhood. J Clin Endocrinol Metab 2000;85:3262-3265.
5. Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP: Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical cure. J Clin Endocrinol Metab 1994;78:131-137.
6. Strickland AL, Underwood LE, Voina SJ, French FS, Van Wyk JJ: Growth retardation in Cushing's syndrome. Am J Dis Child 1972;123:207-213.
7. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP et al: Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88:5593-5602.
8. Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J: Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. Eur J Endocrinol 2006;154:109-118.
9. Mancini T, Doga M, Mazziotti G, Giustina A: Cushing's syndrome and bone. Pituitary 2004;7:249-252.
10. Dupuis CC, Storr HL, Perry LA, Ho JTF, Ahmed L, Ong KK et al: Abnormal puberty in paediatric Cushing's disease; relationships with adrenal androgens, sex hormone binding globulin and gonadotrophin concentrations. Clin Endocrinol (Oxf) 2006.
11. Baron J, Huang Z, Oerter KE, Bacher JD, Cutler GB Jr: Dexamethasone acts locally to inhibit longitudinal bone growth in rabbits. Am J Physiol 1992;263:E489-E492.
12. Koedam JA, Smink JJ, Buul-Offers SC: Glucocorticoids inhibit vascular endothelial growth factor expression in growth plate chondrocytes. Mol Cell Endocrinol 2002;197:35-44.
13. Lindberg MK, Vandenput L, Moverare SS, Vanderschueren D, Boonen S, Bouillon R et al: Androgens and the skeleton: Minerva Endocrinol 2005;30:15-25.
14. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C: Androgens and bone. Endocr Rev 2004;25:389-425.
15. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A: Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006;17:144-149.
16. Scommegna S, Greening JP, Storr HL, Davies KM, Shaw NJ, Monson JP et al: Bone mineral density at diagnosis and following successful treatment of pediatric Cushing's disease. J Endocrinol Invest 2005;28:231-235.
17. Storr HL, Afshar F, Matson M, Sabin I, Davies KM, Evanson J et al: Factors influencing cure by transsphenoidal selective adenomectomy in paediatric Cushing's disease. Eur J Endocrinol 2005;152:825-833.
18. Newell-Price J, Trainer P, Besser M, Grossman A: The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998;19:647-672.
19. Storr HL, Plowman PN, Carroll PV, Francois I, Krassas GE, Afshar F et al: Clinical and endocrine responses to pituitary radiotherapy in pediatric Cushing's disease: an effective second-line treatment. J Clin Endocrinol Metab 2003;88:34-37.
20. Cameron N: The Measurement of Human Growth. London, Croom Helm, 1984.
21. Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA: Cross-sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995;73:17-24.
22. Tanner JM: Growth at Adolescence, ed 2. Oxford, Blackwell, 1962.
23. Tanner JM, Healy MJR, Goldstein H, Cameron N: Assessment of Skeletal Maturity and Prediction of Adult Height (TW3 Method), ed 3. London, Harcourt, 2001.
24. Jux C, Leiber K, Hugel U, Blum W, Ohlsson C, Klaus G et al: Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-I production and expression of GH- and IGF-I-receptor in cultured rat chondrocytes. Endocrinology 1998;139:3296-3305.
25. Unterman TG, Phillips LS: Glucocorticoid effects on somatomedins and somatomedin inhibitors. J Clin Endocrinol Metab 1985;61:618-626.
26. Devoe DJ, Miller WL, Conte FA, Kaplan SL, Grumbach MM, Rosenthal SM et al: Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 1997;82:3196-3202.
27. Di Somma C, Pivonello R, Loche S, Faggiano A, Klain M, Salvatore M et al: Effect of two years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol (Oxf) 2003;58:302-308.
28. Manning PJ, Evans MC, Reid IR: Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol (Oxf) 1992;36:229-234.
29. Salt AT, Savage MO, Grant DB: Growth patterns after surgery for virilising adrenocortical adenoma. Arch Dis Child 1992;67:234-236.